Syndesi Therapeutics

Chemin Du Cyclotron 6

1348 Ottignies-Louvain-La-Neuve

BE

Syndesi Therapeutics

Foundation date

19/12/2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.

Upcoming events

Latest news

  • Mithra appoints experienced life sciences executive Christian Homsy* as Chairman

    18 hours ago

  • Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema

    Friday May 26th 2023

  • How garbage disposal clogs in cells can lead to Alzheimer’s

    Friday May 26th 2023